DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/x5zvjs/dyslipidemia) has announced the addition of Decision Resources, Inc's new report "Dyslipidemia (Event Driven)" to their offering.
As one of the most prevalent yet underdiagnosed and undertreated diseases in the major pharmaceutical markets, dyslipidemia has the potential to represent a compelling commercial opportunity for the manufacturers of both new and existing drugs. Although the excellent efficacy, safety and tolerability, and increasing generic availability, of the statins means these drugs will continue to dominate early lines of therapy, substantial opportunity awaits nonstatin drugs that can convincingly show clinical benefits on a statin background.
However, the barriers to market entry for novel drugs are higher than ever before, with premarketing cardiovascular outcomes trials now a normal requirement, and ever-tighter healthcare payer budgets pushing physicians to prescribe generics. The dearth of nonstatin therapies that target non-LDL-C and possess convincing CV outcomes data means that the greatest commercial potential exists for novel drugs that target the growing population of mixed dyslipidemiaas long as these novel drugs are supported by positive outcomes data.
Key Topics Covered:
What are the key parameters of the dyslipidemia market?
What factors are driving the market for dyslipidemia therapies?
What factors are constraining the market for dyslipidemia therapies?
What are the drug development activities of note in dyslipidemia?
What do the experts say?
What key challenges and opportunities remain?
1 Etiology and Pathophysiology
2 Epidemiology and Patient Populations
3 Current Therapies and Medical Practice
4 Unmet Needs
5 Emerging Therapies
6 Market Outlook
Tables and Figures
For more information visit http://www.researchandmarkets.com/research/x5zvjs/dyslipidemia
Source: Decision Resources, Inc
Source: Research and Markets